Feedback on cancer drugs from people affected by cancer and clinicians
The Canadian Cancer Society is dedicated to improving the lives of people with cancer. We collect feedback about cancer drugs from people with cancer, their caregivers, and clinicians as part of this effort. This feedback helps shape recommendations for which drugs are covered under provincial and territorial drug plans.We share your feedback with two organizations. The Canadian Agency for Drugs and Technologies in Health (CADTH) is an independent, not-for-profit organization. It provides evidence and recommendations about medical procedures, devices and drugs (among other things) to healthcare decision-makers. The National Institute of Excellence in Health and Social Services (INESSS) promotes best practices and the efficient use of resources for health and social services. To ensure adequate representation across the cancer continuum, we will be focusing primarily on rare cancers and those that do not have representation through another organization.
People with cancer and their caregivers
Current Feedback Opportunities @(Model.HeadingTag)>
Past submissions @(Model.HeadingTag)>
To view submissions that have been made to CADTH, including those made by CCS, please visit CADTH’s Reimbursement Review Reports. (Note that it takes time for the submissions to be posted to this site, so you may need to check back to find the results of a specific CCS submission.)
Indication: Dostarlimab is indicated for monotherapy for the treatment of adult patients with recurrent or advanced mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) endometrial cancer (EC) that has progressed on or following prior treatment with a platinum containing regimen.
Indication: Retevmo is indicated as monotherapy for the treatment of RET-mutant medullary thyroid cancer in adult and pediatric patients 12 years of age and older with unresectable advanced or metastatic disease, RET fusion-positive differentiated thyroid carcinoma in adult patients with advanced or metastatic disease (not amenable to surgery or radioactive iodine therapy) following prior treatment with sorafenib and/or lenvatinib.
Leuprolide mesylate (Camcevi)
Indication: Camcevi is indicated for the palliative treatment of advanced prostate cancer. Camcevi 42 mg is indicated for the treatment of hormone-dependent advanced prostate cancer and for the treatment of high-risk localized and locally advanced hormone-dependent prostate cancer in combination with radiotherapy.
Indication: Treatment of adult and adolescent patients 12 years of age and older with differentiated thyroid carcinoma (papillary and follicular together) that has progressed following prior therapy and who are radioactive iodine-resistant or are not eligible for radioactive iodine therapies.
Indication: Darolutamide is indicated for the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC) in combination with docetaxel.
Abiraterone acetate and prednisolone
Indication: For the treatment of high-risk non-metastatic prostate cancer.
Abiraterone acetate and prednisone/dexamethasone with
Indication: For the treatment of metastatic castration-sensitive prostate cancer in combination with androgen deprivation therapy.
Lutetium vipivotide tetraxetan (Pluvicto)
Indication: The treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with anti-androgen drugs and taxane-based chemotherapy or who are not medically suitable for taxane based chemotherapy.